Case Report: Immune Checkpoint Inhibitor-Induced Exuberant Tumor Inflammation With Accelerated Clinical Deterioration in Metastatic Renal Cell Carcinoma

Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy. Nivolumab, an anti-PD-1 monoclonal antibody, markedly improved overall survival in advanced renal cell carcinoma (RCC). However, ICIs can rarely trigger massive inflammation, a phenomenon characterized by rapid acceleration in r...

Descripción completa

Detalles Bibliográficos
Autores principales: Gopalakrishnan, Dharmesh, Jain, Rohit K., Herbst, Laurie, Sikorski, Marcus, Mandava, Silpa, Azabdaftari, Gissou, Xu, Bo, LeVea, Charles, Robillard, Kevin, Ernstoff, Marc S., George, Saby
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8117341/
https://www.ncbi.nlm.nih.gov/pubmed/33996609
http://dx.doi.org/10.3389/fonc.2021.679177

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8117341/
https://www.ncbi.nlm.nih.gov/pubmed/33996609
http://dx.doi.org/10.3389/fonc.2021.679177

Ejemplares similares